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Abstract 
Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) 
have been known for decades to mediate neuroendocrine and vasodilative actions via G-protein- 
coupled receptors of Class B. These are targets of imaging probes for positron emission tomogra-
phy (PET) or single photon emission tomography (SPECT) in tumor diagnostics and tumor grading. 
However, they play only a subordinate role in the development of tracers for brain imaging. Diffi-
culties in development of non-peptide ligands typical for cerebral receptors of PACAP and VIP are 
shared by all members of Class B receptor family. Essential landmarks have been confirmed for 
understanding of structural details of Class B receptor molecular signalling during the last five 
years. High relevance in the explanation of problems in ligand development for these receptors is 
admitted to the large N-terminal ectodomain markedly different from Class A receptor binding 
sites and poorly suitable as orthosteric binding sites for the most small-molecule compounds. The 
present study is focused on the recently available receptor ligands for PAC1, VPAC1 and VPAC2 
receptors as well as potential small-molecule lead structures suitable for use in PET or SPECT. Re-
cently, biaryl, cyanothiophene and pentanamide structures with affinities in nM-range have been 
proposed as non-peptide ligands at VPAC1 and VPAC2 receptors. However, most of these ligands 
have been classified as non-competitive related to the orthosteric binding site of endogenous pep-
tide ligands of VPAC receptors. For PAC1 receptors have been identified hydrazide compounds for 
which an inhibitory and potentially competitive mechanism of receptor binding has been post-
ulated based on molecular docking studies. 
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1. Introduction 
Vasoactive intestinal peptide (VIP) [1] [2] and pituitary adenylate cyclase activating peptide (PACAP) [3] [4] 
activate three types of G-protein-coupled receptors (GPCR) which belong to the Class B receptor family (secre-
tin/glucagon/VIP receptors) and have been intensively investigated [5]-[7] for their structure-activity relation-
ships (SAR) and localization in peripheral tissues and CNS [8]-[11]. These PAC1, VPAC1 and VPAC2 recep-
tors can be found in special regions of brain and spinal cord in densities potentially suitable for in vivo imaging 
with high affinity radiotracer ligands [9]. High attention is paid to these receptors in the areas of pulmology, 
immunology, diabetology, ophtalmology as well as traumatology predominantly for the development of effec-
tive therapeutics [12]-[19]. However, such receptors are rather outsiders regarding successes in brain imaging 
with positron emission tomography (PET) and single photon emission tomography (SPECT). Brain disorders 
providing potential therapeutic applications for ligands of these receptors include chronic inflammatory diseases, 
neurodegenerative disorders, schizophrenia and stress reactions [14] [15] [20] [21]. The diagnostic possibilities 
of small-molecule PET-receptor ligands have been not finally assessed up to now. Modern crystallographic and 
molecular biological methods allowed the discovery of functional variations of these receptors to play a role in 
the switch between distinct regulatory pathways and permit insights in the manifold regulatory possibilities of 
these structures [10] [22]-[25] as well as of species differences [26]. However, only few non-peptide small-mo- 
lecule ligands are available for receptors of VIP and PACAP hitherto. But other Class B GPCR receptors, cha-
racterized by similar conformations of the N-terminal ectodomain (N-ted), have been a target of in vivo neuroi-
maging experiments for detection of disease-related alterations for many years. Some success has been reported 
in the development of positron-emitter-labelled non-peptide compounds. Thus, in vivo trials were reported for 
imaging of ligands of corticotrophin releasing factor receptors (CRFR) and of calcitonin gene-related peptide 
receptors (CGRPR) in monkeys in 2007 [27]-[29] and 2013 [30], respectively.  
Structural differences between the N-teds recently described for Class A and Class B GPCRs as binding sites 
for endogenous peptides have been confirmed also by crystallographic studies [31]-[37]. Additionally, receptor 
activity modulating proteins (RAMP) have been found for almost all Class B receptors up to now (cf. Table 1). 
 
 
Figure 1. Simplified schematic comparison of the N-teds of Class A and Class B receptors. 
Three potential binding sites of small molecule ligands (mauve) at Class B receptors and 
RAMP are indicated. Modified according to [48] [84] [132] [133] (yellow: ligand of the 
receptor, dark blue: N-terminal ectodomain of the receptor; light blue: 7 TM domain.       
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The tasks of these accessory transmembrane proteins have been assigned to the field of the support of the recep-
tor protein in trafficking via the endoplasmatic reticulum to the cellular membrane [35] [41] [42]. Furthermore, a 
potential role of the RAMP ectodomain in the binding of drugs and imaging probes has been suggested [43] (cf. 
Figure 1; cf. Figure 2). 
 
 
Figure 2. Some recently discussed functional determinants of Class B receptor signalling. Large N-ted (N-terminal extracel-
lular domain): is the critical structure discussed in the “two domain model” [84] (ligand binding to the N-ted domain initiates 
a conformation which allows access of the ligand to transmembrane or juxtamembrane orthosteric binding site) and in the 
“hidden agonist model” (binding of a ligand opens the real binding site for an endogenous agonist) [84] [86]. Helix structure 
of endogenous peptide ligands: relatively large endoligands allow positioning at the N-ted which cannot easily mimicked by 
small molecules. RAMP: contribute to trafficking of receptors and their progenitor proteins to the cellular membrane and can 
be involved in ligand binding at the membrane receptor. CLR: (calcitonin receptor-like receptor): GPCR forming by hetero-
dimerization with different RAMPs several receptor subfamilies. Arrestins: regulatory key signalling proteins probably sim-
ilar important like G proteins and determining for bias to long- or short-term actions of the receptors. RANTES: microglia 
mediated mechanism of neuroprotection. Proteasomes: key units of protein catabolism following receptor internalization. 
Limited capacity might facilitate disturbances of protein folding or protein misfolding.                                   
 
Table 1. Some Class B receptors and interactions with RAMP subtypes reported to date.                                
Receptor Interacts with Reference 
CFR1 RAMP2 [38] 
CGRP RAMP1 [39] 
CT RAMP1-3 [39] 
AM1 RAMP2 [36] 
AM2 RAMP3 [36] 
AMY1-3 RAMP1-3 [36] 
VPAC1 RAMP1-3 [39] [40] 
VPAC2 RAMP1-3 [38] 
PTH1 RAMP2 [39] 
PTH2 RAMP3 [36] 
Secretin RAMP2 [39] 
Glucagon RAMP3 [40] 
GLP-1  [38] 
GLP-2  [38] 
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Labelling of ligands at VIP and PACAP specific receptors with PET or SPECT isotopes has been confined 
predominantly to peptide compounds which are applied or developed for localization, grading and therapy of 
cancers [44] [45]. Ligands of VPAC1 and VPAC2 receptors have been employed predominantly for the identi-
fication of adenocarcinoma of breast, tumors of prostate, liver, stomach as well as of small cell lung cancer [45]. 
Non-peptide compounds up to now achieved affinities rather in submicromolar than in subnanomolar range. 
Reports on in vivo imaging experiments are not available. First small molecules of this kind were identified as 
ligands of the PAC1 receptor seven years ago [46]. An antagonist of the VPAC2 receptor was reported two 
years later [47]. The present study regards the first lead structures for its pharmacokinetic and binding properties, 
some further progress in development of VPAC and PAC receptor tracers as well as some of its limitations. 
2. VPAC1, VPAC2, PAC1 Receptors and Their Peptide Ligands 
2.1. Endogenous Ligands PACAP and VIP  
The endogenous ligands at these receptors, PACAP (27 or 38 a.a.r.) and VIP (28 a.a.r.), share some common 
features with other peptide ligands of the secretin-glucagon family of GPCRs.  
The endogenous ligands of Class B receptors have amino acid sequences in the range between 27 and 44 a.a.r. 
in mammalian. They are synthetized by endocrine cells, neurons or immune cells. They form α helices and con-
tain an NCap structure in the N-terminal part [18] [48] [49]. PACAP has been recognized as a compound acting 
as hormone, neurohormone, neurotransmitter and neurotrophic factor [50]. It is found in the brain, cardiovascu-
lar system, thyroid, pituitary, adrenal gland and placenta [10] [13] [51]-[53]. Both, PACAP and VIP, are re-
garded as master switches of circadian rhythm [54] [55]. For VIP its role as regulator of growth of whole fetus 
and of the embryonic brain has been classified as another important long-term effect, while short- term activities 
with involvement of VIP include exocrine secretion, hormone release, muscle relaxation and metabolic actions 
[18]. Furthermore, VIP is involved in neuroprotective, antiinflammatory and immunmodulatory effects and in-
fluences cell proliferation in cancer cells [10]. The level of PACAP38 in adult brain of mice has been found in 
the range of 120 fmol/mg protein and the level of VIP at 500 fmol/mg protein [56]. The levels of both peptides 
are changing from embryonic to adult age in murine brain [57]. PACAP was found at 24 fmol/mg protein at 
postnatal day 1 and VIP at 9.4 fmol/mg protein [56] at the same stage of development. PACAP achieves levels 
of the adult brain some days earlier than VIP. It binds to PAC1 with 1000 fold higher affinity than VIP but 
shows similar affinities to VPAC receptors like VIP [58].  
The selectivity between the three relevant receptors has been investigated in models of SAR at first for VIP 
[59] [60], and subsequently also for PACAP [25] [58]. The first concise pharmacophore model of VIP at 
VPAC1 and VPAC2 receptors with systematic description of functional relevance of all a.a.r.s was provided by 
Nicole et al. (2000) [59]. A characterization of PACAP at the PAC1 receptor was later presented by Sun et al. 
[58] and Kumar et al. [23]. Nicole et al. identified T11 and N28 by alanine scanning, energetic optimization as 
well as investigations of pharmacodynamics as pivotal structures for the binding of VIP to VPAC receptors. For 
PACAP38, it has been observed that the removal of the first five amino acids can transform the polypeptide 
from an agonist at the PAC1 receptor into an antagonist without alteration of the binding affinity [58] [61]. 
Regarding the functional roles of the peptides, for PACAP essential part of attention has been paid to its con-
tribution to stress response [24], whereas the main fields for VIP investigation are inflammatory diseases [62] 
and its cytokine-like role. However, for both peptides have been shown influences of knock-out on behavioral 
functions and on early development in mammals too [24] [35] [63], e.g. in PACAP and VIP deficient mice was 
demonstrated an increase of locomotor activity in open field [56]. On the other hand, VPAC2 deficient mice 
have been shown to be more vulnerable to inductors of experimental colitis than their wild-type littermates [64]. 
Recently, a potential suitability of PACAP as a predictor of outcome from acute intracerebral ischaemia has 
been suggested by clinical studies [65] [66]. PACAP38/PAC1 signalling was demonstrated to be an important 
factor in regulation of trafficking of bone marrow cells which could facilitate their travel to vascular niches after 
focal cerebral ischaemia [66]. Already 2011 Ressler et al. [67] demonstrated that single nucleotide polymor-
phisms in the genes of PACAP (ADCYAP1) and PAC1 receptors (ADCYAP1R1) or methylation of the recep-
tors mRNA can result in postischaemic stress disorder. Moreover, altered VIP levels have been described in ob-
ese women (low levels) and patients with anorexia nervosa [68] [69]. Furthermore, VIP is suggested to be in-
volved in circuits regulating stimulation of the dentate subgranular stem cell niche and it is co-expressed by 
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GABAergic neurons located in hippocampal regions close to this proliferatively important region [11]. For 
PACAP and VIP have been discovered direct and indirect neuroprotection via microglia mediated mechanisms 
(RANTES; CC chemokine Regulated upon Activation, Normal T cell Expressed and Secreted; MIP; macro-
phage inflammatory protein; ADNF; activity dependent neurotrophic factor) and for PACAP has been discussed 
a stimulation of chemokine release by microglia for inhibition of gp120 co-repressors like CCR3, CCR5 and 
CXCR4-a mechanism possibly of relevance for the protection against HIV [26] [70]. High attention has been 
paid to the presence of VIP in lung and bronchial tissue [71]-[73]. A high VIP content in the lung [74] was one 
of the main triggers of the ligand research on VPAC receptors. 
2.2. PAC and VPAC Receptors 
Most of the binding data on vasoactive intestinal peptide receptors were measured in cellular systems with 
overexpression of wild-type and mutated types of the three target receptors. For chicken PAC1 receptors Za-
wilska et al. [9] ranked the affinities of the endogenous peptides in the following order: PACAP38~PACAP27 > 
PACAP6-27~PACAP6-38 > chicken VIP (cVIP) > mammalian VIP and secretin (inactive) [9]. The highest 
density in chicken cortical membranes has been demonstrated with 457 fmol/mg for the PAC1 receptor [9] and 
in mouse whole brain membranes with 857 fmol/ mg protein [75] using [125I]-PACAP27 as receptor ligand. In 
guinea pig cerebral cortex maximal binding of [125I]VIP (human /rat/porcine) was reported by Zawilska et al. 
2005 [76] with 77 fmol/mg protein without differentiation of the receptor subtypes and the authors provided rel-
ative rank order of potency: cVIP ≥ PACAP38~PACAP27~guinea pig VIP (gpVIP) > mammalian VIP (mVIP) > 
peptide-histidine-methionine (PHM) > peptide-histidine-isoleucine (PHI) > secretin [76]. Main localizations of 
PAC1 receptors are neurogenic regions like subventricular zone of olfactory bulb and dentate gyrus [10]. Im-
munohistochemical investigations suggest high levels of PAC1 receptors also in layer I of the cerebral cortex, 
very high density of the receptor in hypothalamus, brainstem, midbrain and hindbrain, and in cerebellar nuclei. 
[57] [58] [77]. 
In turn, PAC1 has been reported to be of less importance in hippocampal regions than VPAC receptors [75] 
[78]. 
Autoradiographic and membrane binding assay data as well as species differences have been described also 
for peripheral tissue [12]. Comparison of [125I]VIP binding at receptors of the lung in human and guinea pig tis-
sues reveals Bmax values of 11.2 fmol/mg protein and 226 fmol/mg protein, respectively, for the high affinity 
binding site and 589 fmol/mg protein and 1730 fmol/mg protein at the low affinity binding sites. For the rat lung 
have been reported Bmax of 584 fmol/mg protein [73]. 
For PAC1 receptors in rodents (PACAP38, Kd 0.5 nM, for comparison VIP-affinity > 500 nM) have been 
identified six splice variants relevant for the third intracellular loop which is coupled to G-proteins [79]. The two 
exons hip and hop, spliced in or out determine different PAC1 receptor variants triggering different signalling 
pathways [9] [24]. Moreover, splice variants with change in the a.a.r. sequence of the N-ted in position 21 have 
been described [5]-[7] which bind PACAP27, PACAP38 and VIP with similar affinity [5]-[7]. 
Activation pathways related to neuroproliferation are regulated via Gq and Gi proteins [80] and via interaction 
with mitogen-activated protein kinase MAP-Kinase and arrestins which provide the regulatory input to receptor 
internalization, desensitization and proteolytic processes as well as to heteromeric signal protein complex acti-
vation. The preferred binding sites of VIP are the N-teds of VPAC1 and VPAC2 receptors (KD 1 nM) [81], 
which mediate their intracellular actions via Gs proteins, but also via Gq and Go proteins. They also trigger cal-
cium release as well as interact with RAMP1-3 (receptor activity modifying protein) (cf. Table 1). A differentia-
tion between the VPAC receptor subtypes predominantly became possible by the discovery of helodermin ob-
tained from gila monster venom [9] [82] [83]. The peptide shows some homology to PACAP and VIP. 
Whereas Nicole et al. [59] had supplied a first systematic functional classification of VIP and PACAP a.a.r. 
components, Laburthe et al. (2007) [83] discussed critically basing on these data two different models of the 
mechanism in which VPAC receptors and especially its N-ted can transfer its endogenous ligands within the 
transmembrane/juxtamembrane domain (J-domain) of the receptor as well as close to intracellular loops (here 
IL3) involved in G proteins activation [84]-[86]. Endogenous peptide ligands [35] [87] [88] bind by their 
C-terminal portion to the extracellular domain whereas the N-terminus of the endogenous ligands interacts with 
the 7TMD structures of the receptors. All Class-B receptors are distinct from Class A receptors by the typically 
large N-ted (100 - 160 a.a.r, [36] [47]) with consensus repeat or Sushi domain core formed by two antiparallel β 
sheets connected via three disulfide bonds between six cysteine residues and a salt bridge. This feature is re-
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garded as the signature of Class B receptors, even if a full length structure of Class B receptors is yet not availa-
ble [61] [84].  
VPAC1 is expressed in lung, small intestine, thymus, kidney and brain [10] [63] [78] [89] [90]. In the brain 
VPAC receptors are expressed in piriform cortex, cerebral cortex, dentate gyrus, hippocampus, lateral amygda-
loid nucleus, caudate putamen, nucleus supraopticus, thalamic nuclei, choroid plexus and pineal gland as well as 
cerebellar cortex and deep cerebellar nuclei [11] [77]. Bmax values for the binding of [125I]cVIP and [125I]PACAP 
have been obtained for chicken hypothalamus and chicken cortical cerebral membranes respectively. [125I]cVIP 
has been shown to bind with 167 fmol/mg protein to chicken hypothalamic membranes [8]~1/3 of the Bmax for 
[125I] PACAP in cortical cerebral membranes of the same species [9].  
Also the main target receptors of VIP as there are VPAC1 and VPAC2 have different pharmacology and dis-
tributions [5] [91]. E.g. VIP had a 4 fold higher affinity for hVPAC1 than for VPAC2 [60] [61]. 
The VPAC2 receptor is suggested to mediate activation of insulin secretion [91] [92], while VPAC1 receptors 
according to their expression pattern are suggested to contribute to the increase of hepatic glucose production 
[93]-[95] but also to attenuation of diabetes related inflammation [96]. 
On the other hand, [24] chromosomal site duplication can result in serious neuroanatomic retardation [24] and 
characteristic mental diseases, e.g. alterations of VPAC2 expression by chromosomal site duplication can carry 
the risk of schizophrenia and autism [97]. In turn, VPAC2 receptor-deficient mice showed growth retardation [98]. 
PAC1 knock-out mice have been reported to show mortality close to 60% during the first four weeks after 
birth. Surviving mice are characterized by a accelerated decrease in social investigations and less aggressively 
male animals but higher sexual activity. The experiments suggested that PACAP could be a counterpart of the 
vasopressin-oxytocin system [99]. Furthermore, PAC1 deficient mice were shown to develop reduction of an-
xiety-like behaviour [100]. 
2.3. Synthetic Peptide Ligands  
Labelling of synthetic peptide ligands with PET and SPECT isotopes for recognition of VPAC and PAC recep-
tors for diagnostic and therapeutic purposes include 99mTc, 18F, 123I, 68Ga, 64Cu and 111In labelled compounds, 
which are prepared using distinct chelating agents or prosthetic groups [45]. Somatostatin and its labelled ana-
logues (e.g. [111In] octreotide) are the most frequently clinically used peptides in tumor diagnostics. However, 
also further peptide receptor ligands are more and more in the focus of tumor visualization. E.g. bombesin pep-
tides labelled with 18F and 99mTc have been already described in studies with VPAC receptor ligands in the early 
years of this century. The overexpression of VPAC receptors, however, also in normal tissues of some organs 
restricts the efficiency of such peptide probes as tools in tumor identification [45]. Other applications e.g. the 
imaging of brain receptors are limited by vulnerability of the peptides to enzymatic breakdown and low in vitro- 
stability. Some success could be achieved by reconstituted peptides containing mutations in selected parts of the 
molecule, intramolecular ring structures, introduction of lactam ringsor acylation of the N-terminus of VIP [101]. 
Furthermore, the connection with polyethylene glycol (PEG) was used to improve the pharmacokinetic properties.  
2.3.1. Peptide Ligands at VPAC1 Receptor  
Nicole et al. (2000) [59] observed, that alanine exchange of VIP a.a.r. in positions 11, 22 and 28 results in bind-
ing with 10-8M affinity at VPAC1 receptor what is close to the affinity of VIP itself. In contrast, the binding af-
finity at VPAC2 receptors decreases by one order of magnitude after such substitution. Consequently, 
[Ala11,22,28]VIP is classified as the most selective agonist at human VPAC1 receptor. 
Peptide ligands at VPAC1 receptors (cf. Table 2) attract attention predominantly as in vitro probes for the 
characterization of their target receptors but maintain in part also affinities to VPAC2 and PAC1 receptors. PG 
96-238 and PG 97-465 are antagonist and agonist at the VPAC1 receptor, respectively, but also antagonist at 
VPAC2 and agonists at PAC1 receptor (cf. Table 2). PGI 97-278 is partial antagonist at the VPAC1 receptor 
and agonist at the VPAC2 receptor [101]. The extension of the VIP sequences VIP (1 - 24) or VIP (1 - 26) by 
the carboxyl terminal part of Ro 25-1553 (DLKKGGT or KKGGT) decreased the affinity at VPAC1 receptors 
but altered not the affinity at VPAC2 receptors.  
2.3.2. Peptide Ligands at VPAC2 Receptor  
For different therapeutic purposes some VIP and PACAP related peptides have been synthesized and shown to  
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Table 2. Some peptide ligands of VPAC1, VPAC2 and PAC1 receptor* and their role as agonists or antagonist at these re-
ceptors.                                                                                               
Peptide CAS-no VPAC1R VPAC2R PAC1R References 
VIP 37221-79-7 agonist agonist  [102] 
PG-96-237     [101] 
PG 96-238 309728-48-1 antagonist antagonist partial agonist [95] 
PG 97-269 202463-00-1 antagonist   [103] [104] 
PG 97-277 139308543 partial agonist   [101] 
PG 97-278 1392912-99-0 partial antagonist agonist  [101] 
PG 99-465 309913-26-6 fullagonist antagonist partial agonist fullagonist [47] [101] [104] [105] 
Bay 55-9837 46390-25-8  agonist  [10] [16] [55] [103] [106]  
Ro 25-1392 150828-75-4  agonist  [107] 
Ro 25-1553 159704-87-6  agonist  [71] [102] 
[Ala11,22,28]VIP  antagonist   [59] 
PACAP (6-38) 143748-18.9 antagonist antagonist antagonist [47] [63] [104] [109] 
M65    antagonist [109] 
Maxadilan  515114-03-1   agonist [63] [110] [111]  
Maxadilan d.4   antagonist  [63] [110] [111] 
PACAP27 129069-75-6   agonist [109] 
PACAP38 137061-48-4   agonist [109] 
*peptide sequences: VIP: HSDAVFTDNYTRLRKQMAVKKYLNSILN; PG 96-237: AcHSDAVFTENYTKLRKRNleAAKKYLNDLKKGGT; PG 
96-238: -FTENYTKL-RKRNleAAKKYLNDLKKGGT (20-16)lactam; PG 97-269: AcHD-PheDAVFTNSYRKVLKRLSARKLLQDIL; PG 97-277: 
N-Ac-HSDAVFTENYTKLEKRNle-AAKNleYLNNLKKGG-threonine amide; PG 97-278: AcHDPheDAVFTENYTKLRKRNleAAKNleYLNN- 
LKKGGT; PG 99-465: N-(1-oxotetradecyl) HSDAVFTDNYTKLRKQMAVKKYLNSIKKGGT; Bay 55-9837:  
HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY; Ro 25-1392: AcHSDAVFTEN-O-methyl-YTKLRKQNleAAKKYLNDLKK(25-21)lactam; Ro 
25-1553: AcHSDAVFTENYTKLRKQNleAAKKYLNDLKKGGT;PACAP (6-38): 
TDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK; M65: CDATCQFR-KAIDDCQKQAHHSN-VLLPGNSVFKECMKQKKKEFKAGK;  
Maxadilan: ATCQFRKAIDDCQKQAHHSNVLQTSVQTTATFTSMDTSQLPGNSVFKECMKQKKKEFKAGK; 
Maxadilan d.4: CDATCQFRKAIDDCQKQAHHSNV-PGNSVFKECMKQKKKEFKAGK;  
PACAP27: HSDGIFTDSYSRYRKQMAVKKYLAAVL; PACAP38: HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKRYKQRVKNK 
 
interact with VPAC2 receptors. This is not only limited to tumor diagnostics but include also applications in 
metabolic diseases. Thus the possibility of a decrease of glucose levels has been investigated. The peptide BAY 
55 - 9837 had been identified as an effective glucose suppressing compound by an agonist action via VPAC2 
receptors. [16] [106]. However, the compound showed degradation at the N-terminus and deamidation at aspa-
ragine [106]. Pan et al. could improve the stability by mutations in the positions 9 and 28 and obtained BAY 
(Q9Q28) which showed the same affinity at VPAC2 receptors like the original compound. However, it was sta-
ble for four weeks at 40˚C, while BAY 55 - 9837 was degradated by 80% within two weeks. Coupling the re-
constituted compound via the cysteine residue C32 to polyethylene glycol (22 or 43 kDa) resulted in stable 
compounds. Best conservation of the in vitro functionality after pegylation was observed with 22 kDA polye-
thylene glycol. Both pegylated forms were active in vivo, for three and six hours post s.c. injection. General in 
vivo action was improved and the glucose lowering effect was maintained, while in vitro activities were reduced 
by pegylation. Mutations in the first a.a.r.s of the N-terminus resulted in reduced flexibility of the ectodomain 
and consequently a reduced affinity at VPAC2 receptors [106].  
BAY55-9837 has been proposed recently as a potential protective drug in spinal muscular atrophy in distinct 
mouse models [112]. Spinal muscular atrophy is a rare disease (incidence 1:11,000) but a leading genetic cause 
of pediatric death [112] [113]. BAY 55-9837 is presumed to activate via binding at VPAC2 receptors the p38 
pathway and to enhance the Survival of Motor Neuron proteins (SMN) type 2 inhibiting the progression of spin-
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al muscular atrophy [108]. 
All the peptide ligands bind orthosterically at the N-terminal ectodomain of their target receptors [47]. But 
that makes it difficult to develop highly selective ligands for the subtypes of VPAC receptors due to the similari-
ties between the peptides [47].  
The long-acting VIP analogue Ro 25 - 1553 is a peptide with lactam ring at the amino acids 21 to 25 [95]. The 
absence of the lactam bridge in the molecule reduced the affinity of the compound at both subtypes of VPAC 
receptors, but retained a 300 fold selectivity for binding to VPAC2 receptor [94]. This was presumed to be due 
to charged side chains revealed in these compounds under such conditions. Such consequence could be pre-
vented by introduction of a nor-leucine and an asparagine residue at the positions 21 and 25 [101]. Ro 25-1553 
was early tested in forebrain membranes [72] where it could displace [125I]VIP with an IC50 of 4.98 nM. The 
cyclic VIP analogue got especially early attention for its relaxant effect on bronchotracheal tissues in guinea 
pigs and humans [71] [72]. Since 2003 these effects comparable with that of isoproterenol and salbutamol were 
confirmed also in clinical studies [114]. The comparison of the influence of Ro 25-1553 on bronchial and lung 
function with that of salbutamol revealed an equivalent degree of both drugs in protection of pulmonary tissue 
[70]. In guinea pig and human isolated bronchial tissue Ro25 - 1553 could attenuate brochoconstriction induced 
by histamine, LTD4, platelet activating factor or acetylcholine [71]. A further cyclic peptide, Ro 25 - 1392, dis-
placed [125I] VIP with Ki of 9.6 and 16 nM at VPAC2 receptors whereas the affinity at VPAC1 receptors was in 
µM range [17] and only 40% of VPAC receptors the binding sites could be occupied. 
2.3.3. Peptide Ligands at PAC1 Receptor  
For PACAP38 it is known that deletion of the first five a.a.r.s of the peptide transforms it from an agonist to an 
antagonist at the receptor [58]. Mutational and binding data confirm an essential role of these a.a.r.s in the or-
thosteric binding of the C-terminus of the endogenous agonist at the N-terminal ectodomain of the receptor and 
a role of further parts of the peptide in the transfer into vestibular or transmembrane domain of receptor [58] 
[61]. 
The 61 a.a.r. peptide Maxadilan can be obtained from blood seeking flies as lutzomyia longipalpis [101] [115] 
but is available today also as synthetic compound. As a vasodilator with higher efficacy than CGRP it plays a 
role in the infectivity pathway of leishmania conducted by sand fly and does not show close structural similarity 
to PACAP [111] [116]. Maxadilan acts as an agonist at the PAC1 receptor (Table 2). Additionally to the actions 
on vascular tone of arteriolar vessels recently an enhancement of vascular leakage in postcapillary vessels and 
venuels has been described accompanied by a stimulation of leucocyte migration via the CXCR1/2 receptor of 
neutrophils [116]. All these actions are suggested to be mediated via PAC1receptors and can be attenuated by 
the recombinant analogue of Maxadilan, M65 [116]. 
3. Non-Peptide Ligands of VPAC and PAC Receptors 
Until 2010 small molecule ligands had been identified for five of the 15 known Class B GPCRs only [47] [117]. 
Such were antagonists of the CRF1 receptor as SSR125543A, antalarmin, DMP 904, NBI 30775/R121919, NBI 
35965; antagonists at the glucagon receptor as LY 168049, BAY 27 - 9955, NNC25 - 2504;, an antagonist at the 
CGRP receptor: BIBN4096BS; the GLP-1 receptor antagonist T0632 and the calcitonin receptor agonist SUN- 
B8155 [85] [117]. However, these compounds have been discussed rather as allosteric modulators than as drugs 
docking orthosterically and acting competitively [117]. Also for the CGRP receptor ligand MK4232, described 
2013 by Hostetler et al. [30], in first successful PET experiments binding modalities in the brain let open ques-
tions even if the compound was bound to the parts of the brain in a manner reflecting the regions typically 
showing high densities of the receptor [118]. The involvement of non-peptide ligands at VPAC and PAC recep-
tors might extend the spectrum of tracers contributing to the characterization of functional basis of mental dis-
eases and of responses to therapeutic interventions in neurological disorders. It is not finally decided which of 
the recent models [61] [119] for ligand-class C receptor interaction could be a relevant one for the explanation 
of non-peptide ligand actions. 
3.1. Non-Peptide VPAC1 Receptor Ligands 
There had been no reports on small molecule non-peptide ligands of the VPAC1 receptor until Harikrishnan et 
al. (Bristol-Myers Squibb) [90] published 2012 the results of a high throughput screening based on cAMP as-
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says and determination of antiproliferative activity. Three series of potential lead structures were presented pro-
viding moderate binding affinities until 81 nM (biaryl compounds; Figure 3, compounds 1 - 3); 290 nM (cya-
nothiophenes; Figure 4, compounds 4 - 8) and 410 nM (cyanothiophene phenethylamide) compounds 9 and 10; 
Figure 5).  
 
 
Figure 3. Non-peptide ligands of VPAC1 receptors: Biaryl compounds: 1. (2,4-di-tert-butyl-6-(4-fluorophenyl) cyclohexyl) 
methanol; 2. (2,4-di-tert-butyl-6-(4-chlorophenyl) cyclohexyl) methanol; 3. (2,4-die tert-butyl-6-(3,4-dimethylphenyl)-chlo- 
rophenyl) cyclohexyl) methano. ChemDraw (Cambridgesoft.com) was used for verification of IUPAC names.                
 
 
Figure 4. Non-peptide ligands of VPAC1 receptors: Cyanothiopentenes: 4.(E)-N-(3-cyano-4,5,6,7-terahydrobenzo[b] thio- 
phen-2-yl)acetimidic acid; 5. (E)-N-(3-cyano-4,5,6,7-tera-hydro- benzo-[b]thiophen-2-yl) cyclopentane carbimidic acid; 6. 
(E)-N-(3-cyano-4,5,6,7-terahydro-benzo[b]thiophen-2-yl) cyclohexane carbimidic acid; 7. (E)-N-(3-cyano-4,5,6,7-terahy- 
drobenzo[b]thiophen-2-yl) benzimidic acid; 8.(E)-N-(3-cyano-4,5,6,7-terahydrobenzo[b]thiophen-2-yl) acetimidoyl fluoride.  
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Figure 5. Non-peptide ligands of VPAC1 receptors: Propanamide substituted cyanothiophenes: 9. N-(3-cyano-4,5,6,7-te- 
trahydrobenzo [b]thiophe-2-yl)-3-(p-tolyl)propanamide; 10. N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2yl)-3-(4-me- 
thoxyphenyl)propanamide.                                                                                
 
Robl et al. provided in 1990 [120] the synthetic route used by Harikrishnan et al. in a modified mode via for-
mation of a lactone and its aromatization followed by introduction of triflic anhydride which gave via aryl trif-
late finally the biaryl. A series of substitutions at the 2-aryl ring resulted in the best IC50 values for a 3-chloro 
compound (100 nM) and a 3,4 dimethyl compound (81 nM) regarding inhibition of cAMP release. Actions on 
cell proliferation could not be verified. 
The cyanothiophenes stood less active in the same screening assays if various amides had been introduced in-
to the molecules. In general, the introduction of amides coupled to cyclopentyl and hexyl residues resulted in 
better IC50 (until 290 nM) than the small aliphatic or small cyclic motifs. Further modification of phenetylamide 
cyanothiophenes (Figure 5) could not further improve the inhibitory efficacy in cAMP assays additionally [90]. 
3.2. Non-Peptide VPAC2 Receptor Ligands 
Neither orthosterically nor allosterically binding small molecule ligands of VPAC2 receptors were presented un-
til 2010 [47]. The first compound discovered by high throughput screening was a nitrophenyl sulfonamide pen-
tanamide which showed moderate IC50 values for inhibition of VPAC2 receptor-mediated cAMP accumulation 
(IC50 3.8 µM) and for ligand-activated β-arrestin2 binding (IC50 2.3 µM; β arrestin Pathhunter assay). Chu et al. 
(Novartis) pronounciate that only a single lead structure was detected among 1.67 million compounds of their 
data collection. This compound is a non-competitive ligand of the human VPAC2 receptor [47] (Figure 6, 
compound 11). 
One of the main obstacles of the discovery of the small-molecule ligands of class B GPCRs is the absence of 
highly pecific antagonists at VPAC1 and VPAC2 receptors [47]. Peptide ligands typically bind to orthosteric 
binding sites of these receptors. However, usually the structural difference between such peptide ligands are not 
sufficient to discriminate very selectively between the two receptor subtypes. Chu et al. demonstrated for their 
compound in Schild-Plot analysis of cAMP accumulation typical features of non-competitive ligands as the 
mismatch of the slope with requirements for perfect linear regression which would have confirmed competitive 
interaction with the VPAC2 receptor. 
In the β-arrestin assay compound 1 (here compound 11, cf. Figure 6) decreased EC50 of VIP but reduced also 
the maximal level of arrestin binding what fulfills rather the requirements for an allosteric modulator than for a 
competitive antagonist. The compound interacts with a.a.r. in the TM7 region which are, however, not con-
served between human and mouse [47] [84]. 
Compound 2 (here compound 12, Figure 6) is presumed by Chu et al. [47] to activate the VPAC2 receptor 
rather than to act as an antagonist. 
3.3. Non-Peptide PAC1 Receptor Ligands 
A first series of small-molecule antagonists of PAC1 receptors with affinities in the nM range was proposed in 
2008 by Beebe et al. (Abbott Laboratories) [46]. Hydrazides were chosen as lead structures containing three 
cyclic moieties and the authors of the study supplied also first landmarks on potential pharmacophore contribu-
tions of the essential parts of these compounds [25]. Identification of two lead structures was performed by 
means of a compound library using [125I]PACAP27 binding at PAC1 receptors expressed in human embryonic  
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Figure 6. Non-peptide ligands of VPAC2 receptors: Pentanamides: 11. (2R, 4S)-2-benzyl-5-((4(tert-butyl)phenyl)sulfona- 
mido)-4-hydroxy-N-(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1yl)pentanamide; 12. (2R, 4S)-2-benzyl-4-hydroxy-N-(1S, 
2R)-2-hydroxy-2,3-dihydro-1H-inden-1yl)5((4-nitrophenyl)sulfonamide)pentanamide.                                 
 
kidney cells (HEK293f cells). Finally, the structures based on series of alkylidene hydrazides developed by 
Madsen, Ling et al. (Novo-Nordisk ,Pfizer) as glucagon receptor antagonists in 2002 [121]. Most effective 
binding potencies at the PAC1 receptor had been observed for a hydrazide (Figure 7, compound 13) with a Ki of 
56 nM and a hydrazide indole (Figure 7, compound 16, Ki 72 nM) [25] [46]. 
The log P of compounds 13 and 16 are with 5.36 and 6.12 not in an appropriate range for use as probes for 
brain imaging. Modifications of the structure with demethylation in the distal ring, at the middle ring and fluo-
rination at the distal ring can bring the ratio closer to 3 (Figure 7, 15). Beebe et al. [46] revealed in investiga-
tions of structure-activity relationships that alterations in these regions will be only of minor consequences for 
the affinity at the PAC1 receptor. 
Furthermore, the pharmacophore analysis of hydrazide indoles described by Beebe et al. demonstrates the in-
dole moiety tolerates only poor structural modifications. The p-phenol connected by the hydrazide linker with 
the middle ring as well as its m-electron withdrawing group had been identified to be crucial for high potency of 
the compound at the target receptor [46].  
Currently, Wu et al. [25] investigated the potential interaction between the PAC1 receptor and its endogenous 
ligand PACAP38 as well as with the two hydrazides mentioned above (compounds 13 and 16; Figure 7). In 
docking studies of a 3D model of the receptor, the 7TMD of the PAC1 receptor was mimicked by a structure 
based on homology studies on the PTH1 receptor. The signal sequence of the N-terminal ectodomain (N-ted) 
had been removed in this model [25] [122]. Previous experiments with exon 2 -/- mice had demonstrated that 
animals with targeted deletion of the signal peptide are viable, fertile and without morphological differences to 
wild-type animals [122] [123]. 76 and 89 conformations were identified for the binding of compounds 13 and 16 
at the receptor model. In most of them hydrogen bonds were created to the amino acids I63, S100 and G105. 
Best binding conditions were obtained for compound 13 via hydrogen bonds with S100 and E339. The amino 
acid residues 116 - 120 of the N-ted domain had been identified as preferred binding sites of PACAP38. 
Because the signal peptide containing the first 20 amino acids is absent in the model created by Wu et al., the 
S100 corresponds to S120 in the native receptor [125]. The authors predicted that the investigated hydrazide 
compounds can inhibit the interaction of PACAP with the N-ted and prevent also the normal conformational 
consequences for the 7TMD region. They suggested that the compounds produce a steric hindrance for the 
binding of PACAP and inhibit competitively the biological activity of the peptide ligand. 
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Figure 7. Non-peptide ligands of PAC1 receptors: Hydrazides and hydrazide indoles: 13. (E)-3-chloro-4-hydroxy-N’-(4- 
((4-isopropylbenzyl)oxy)-3,5-dimethoxybenzylidene) benzohydrazide; 14. (E)-3-chloro-4-hydroxy-N’-(3-((4-isopropyl- 
benzyl)oxy)-4,5-dimethoxybenzylidene) benzohydrazide;15. (E)-3-chloro-N’-(3-((4-fluorobenzyl)oxy) 5-hydroxy-4-me- 
thoxybenzylidene)-4-hydroxybenzohydrazide; 16. (E)-3-cyano-4-hydroxy-N’((1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-yl) 
methylene) benzohydrazide.                                                                               
4. Summary and Conclusions 
Already early in vivo PET experiments with potential ligands at Class B receptors of the brain revealed pharma-
codynamic constraints for non-peptide ligands in comparison with endogenous peptide ligands of these receptors 
[27] [123] [124]. E.g. investigations on CRF1 receptors using Br-76 and C-11 labelled compounds resulted in 
confined ligand binding and receptor occupancy in the brain which was not sufficient for in vivo visualization of 
regions with enrichment of such receptors. 
Jagoda et al. discussed that related to their 4-[76Br] BMK-152 experiments in monkeys [123], non-peptide, 
small-molecule ligands would be expected to target the juxtamembrane domain (J-domain) either in allosteric or 
competitive manner, depending on conformation of the receptor, but at the extracellular domain they were pre-
sumed to obey to an allosteric mode only [85] [123]. For instance, antalarmin, a well known CRF1 antagonist, 
can trigger Gs or Gi proteins via binding to different states of the J-domain as preferred target structure [117]. 
Finally, the action of small-molecule non-peptide ligands is not ensuring the standard behaviour of the models 
described by Laburthe [84]. Even the most of the small-molecule compounds reported currently are not free of 
the pharmacodynamic drawbacks preventing high affinity ligand-receptor interactions comparable to that of en-
dogenous peptide ligands. 
Hollenstein (2014) suggested that the problems with small molecules were due to the large cave of the N-ted 
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of Class B receptors which can bind the natural peptides and facilitate their approach to the activation motif in a 
region surrounded by the transmembrane domains [33] [36]. Extracellular domains, especially the N-ted of 
Class B receptors are regarded to be not well conserved in comparison to Class A receptors, while there is a 
higher conservation of transmembrane domains (TMD) [125]-[129]. More and more small-molecule ligands are 
described with their TMD binding sites. For instance, Hollenstein currently described the TM3 domain as a 
binding site of a CRF1 ligand [33] [36]. A further potential target site for receptor probes might be at accessory 
proteins like RAMPs (cf. Table 1) which are colocalized with Class B receptors [42]. For calcitonin gene-re- 
lated peptide receptors forming a complex with CLR (calcitonin receptor like receptor) and RAMP1 has been 
shown that the CLR-RAMP1 heterodimer can interact with the small molecule CGRP receptor ligands olcege-
pant and telcagepant [36] [124]. RAMPs have been shown to be involved also in the actions of CRF1 receptor 
[38]; adrenomedullin, amylin, PTH, VPAC and glucagon receptor (cf. Table 1). Relations of small molecules to 
RAMP structures at PAC and VPAC receptors have yet not been investigated. It is known for Class A receptors 
that allosteric interactions with extracellular loops between transmembrane domains of GPCRs can also influ-
ence the cooperativity of the respective domains and finally of the receptors e.g. mAch receptor [127] [130] 
[131]. Such options could be relevant also in Class B receptors. 
The PAC1 receptor is regarded as the most abundant among the three receptors sensitive to PACAP and VIP. 
That’s why the confirmation of a competitive binding mode of the hydrazides and hydrazide indoles described 
by Beebe et al. [46] could be an important step to suitable probes for in vivo imaging. 
However, from the view of pharmacodynamics, the proposed small molecules are yet not able to compete 
with endogenous peptide ligands. Regarding efforts to use such compounds as PET tracers for in vivo visualiza-
tion of PAC or VPAC receptors of the brain, they have to be ranged on a pre-stage of preclinical testing at the 
moment. A pharmacophore model like that developed by Beebe et al. might be a good starting point for the im-
provement and balanced selection of pharmacodynamically and pharmacokinetically relevant alterations of the 
molecules. Docking studies as described by Wu et al. [25] support the further improvement of the preliminary 
lead structures for potential VPAC and PAC receptor ligands and for the selection of best candidates for prec-
linical characterizations and labelling. Site directed mutations as well as knock-out or transgene animal models 
[134] will be helpful tools for better understanding of structure-function relationships as well as in evaluation of 
therapeutic efficacy of potential drugs. But for all of the potential ligands currently available the affinities are 
beyond the requirements allowing in vivo imaging of neuropeptide receptors. The improvement as well as the 
characterization of the selectivity for the target receptors of PACAP and VIP and their subtypes remains a chal-
lenge. 
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Abbreviations 
a.a.r.: amino acid residue;  
ADNF: activity-dependent neurotrophic factor;  
AM: adrenomedullin;  
AMY: amylin;  
CLR: calcitonin receptor-like receptor;  
CT: calcitonin;  
CGRP: calcitonin-gene-related peptide;  
CRF: corticotrophin releasing factor,  
GLP: glucagon-like peptide;  
GPCR: guanine-nucleotide-regulatory-protein-coupled receptor;  
MAP kinase: mitogen-activated protein kinase; 
MIP: macrophage inflammatory protein;  
N-ted: N-terminal ectodomain;  
PACAP: pituitary adenylate cyclase activating polypeptide; 
PAC receptor: pituitary adenylate cyclase activating polypeptide receptor;  
PET: positron emission tomography;  
PHI: peptide-histidine-isoleucine;  
PHM: peptide-histidine-methionin;  
PTH: parathyroid hormone;  
RAMP: receptor activity modifying protein; 
RANTES: CC chemokine Regulated upon Activation, Normal T cell Expressed and Secreted;  
MIP: macrophage inflammatory protein;  
SAR: structure-activity relationships;  
SPECT: single photon emission tomography;  
7TMD: seven transmembrane domains;  
VIP: vasoactive intestinal peptide;  
cVIP: chicken VIP;  
gpVIP: guinea pig VIP;  
mVIP: mammalian VIP;  
VPAC receptor: vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor. 
 
 
